336 related articles for article (PubMed ID: 36232628)
1. Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer.
Nero C; Boldrini L; Lenkowicz J; Giudice MT; Piermattei A; Inzani F; Pasciuto T; Minucci A; Fagotti A; Zannoni G; Valentini V; Scambia G
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232628
[TBL] [Abstract][Full Text] [Related]
2. Deep Learning for Detecting BRCA Mutations in High-Grade Ovarian Cancer Based on an Innovative Tumor Segmentation Method From Whole Slide Images.
Bourgade R; Rabilloud N; Perennec T; Pécot T; Garrec C; Guédon AF; Delnatte C; Bézieau S; Lespagnol A; de Tayrac M; Henno S; Sagan C; Toquet C; Mosnier JF; Kammerer-Jacquet SF; Loussouarn D
Mod Pathol; 2023 Nov; 36(11):100304. PubMed ID: 37580018
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases.
Gallotta V; Conte C; D'Indinosante M; Capoluongo E; Minucci A; De Rose AM; Ardito F; Giuliante F; Di Giorgio A; Zannoni GF; Fagotti A; Margreiter C; Scambia G; Ferrandina G
Eur J Surg Oncol; 2019 Nov; 45(11):2096-2102. PubMed ID: 31227342
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
[TBL] [Abstract][Full Text] [Related]
5. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
6. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
7. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
Tomao F; Bardhi E; Di Pinto A; Sassu CM; Biagioli E; Petrella MC; Palaia I; Muzii L; Colombo N; Panici PB
Cancer Treat Rev; 2019 Nov; 80():101909. PubMed ID: 31629204
[TBL] [Abstract][Full Text] [Related]
8. Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
Cancer Res Treat; 2020 Oct; 52(4):1229-1241. PubMed ID: 32718143
[TBL] [Abstract][Full Text] [Related]
9. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers.
Cowan R; Nobre SP; Pradhan N; Yasukawa M; Zhou QC; Iasonos A; Soslow RA; Arnold AG; Trottier M; Catchings A; Roche KL; Gardner G; Robson M; Abu Rustum NR; Aghajanian C; Cadoo K
Gynecol Oncol; 2021 May; 161(2):521-526. PubMed ID: 33712278
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.
Paik ES; Heo EJ; Choi CH; Kim JH; Kim JW; Kim YM; Park SY; Lee JW; Kim JW; Kim BG
Cancer Sci; 2021 Dec; 112(12):5055-5067. PubMed ID: 34657357
[TBL] [Abstract][Full Text] [Related]
12. Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance.
Romey M; Rodepeter F; Hattesohl A; Kaiser K; Teply-Szymanski J; Heitz F; Staebler A; Serra V; Grass A; Marmé F; Timms KM; Harter P; Llop-Guevara A; Kommoss S; Boekhoff J; Denkert C
Mod Pathol; 2024 Apr; 37(4):100445. PubMed ID: 38341130
[TBL] [Abstract][Full Text] [Related]
13. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
Moschetta M; George A; Kaye SB; Banerjee S
Ann Oncol; 2016 Aug; 27(8):1449-55. PubMed ID: 27037296
[TBL] [Abstract][Full Text] [Related]
14. The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.
Sun C; Li N; Ding D; Weng D; Meng L; Chen G; Ma D
PLoS One; 2014; 9(5):e95285. PubMed ID: 24788697
[TBL] [Abstract][Full Text] [Related]
15. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
16. The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
Haunschild CE; Tewari KS
Gynecol Oncol; 2021 Jan; 160(1):333-345. PubMed ID: 33055011
[TBL] [Abstract][Full Text] [Related]
17. The first Japanese nationwide multicenter study of
Enomoto T; Aoki D; Hattori K; Jinushi M; Kigawa J; Takeshima N; Tsuda H; Watanabe Y; Yoshihara K; Sugiyama T
Int J Gynecol Cancer; 2019 Jul; 29(6):1043-1049. PubMed ID: 31263023
[TBL] [Abstract][Full Text] [Related]
18. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
[TBL] [Abstract][Full Text] [Related]
19. Association of BRCA1/2 mutations with prognosis and surgical cytoreduction outcomes in ovarian cancer patients: An updated meta-analysis.
Wang Y; Li N; Ren Y; Zhao J
J Obstet Gynaecol Res; 2022 Sep; 48(9):2270-2284. PubMed ID: 35698734
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of Clinical Factors Including
Kim JY; Park H; Lee DW; Kim MJ; Shin JE; Lee KE; Lee HN
Anticancer Res; 2022 Oct; 42(10):4945-4954. PubMed ID: 36191979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]